PDE is a treatable disorder of lysine metabolism

Oct 7, 2021·
Curtis Coughlin II
Curtis Coughlin II
· 0 min read
GMDI
Abstract
This talk will focus on the impact of lysine reduction therapies (LRT) on cognitive outcomes and the current consensus guidelines for the diagnosis and management of pyridoxine-dependent epilepsy (PDE-ALDH7A1).
Date
Oct 7, 2021
Event
GMDI webinar series
Location

Virtual

PDE-ALDH7A1
Curtis Coughlin II
Authors
Curtis Coughlin II
Associate Professor
Translational researcher focused on rare diseases and bioethics